Cromos Pharma, where the patients are

April 25, 2014 – News Bytes

R&D Trends

GSK, Novartis, Eli Lilly swap assets to specialize, become more profitable

By Ronald Rosenberg
CenterWatch Staff Writer

In a major swap of assets, three of the world’s largest drug companies have announced a multi-part, $28.5 billion deal that enables Novartis to focus more on cancer, GlaxoSmithKline on vaccines and Eli Lilly on animal health.

CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

April 21

Healthcare IPOs soar in first quarter

Survey compares 'push/pull' tactics in patient recruitment

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

April

Make way for mobile health in clinical trials
Despite patient retention, data quality benefits, regulatory hurdles persist

Global clinical trial laboratories decentralize
Regional labs reducing complexity, delivering cost and time savings

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

March

Strategic alliances hit bumps in the road
Mixed relationship performance driving new approaches

Tapping community hospitals for clinical trial volunteers
New study finds high potential but infrastructure, resources are lacking

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.